Biocryst Pharmaceuticals Stock Price on March 31, 2024
| BCRX Stock | USD 7.60 0.11 1.47% |
Below is the normalized historical share price chart for BioCryst Pharmaceuticals extending back to March 04, 1994. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of BioCryst Pharmaceuticals stands at 7.60, as last reported on the 24th of November, with the highest price reaching 7.66 and the lowest price hitting 7.42 during the day.
If you're considering investing in BioCryst Stock, it is important to understand the factors that can impact its price. BioCryst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0229, which signifies that the company had a -0.0229% return per unit of risk over the last 3 months. BioCryst Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioCryst Pharmaceuticals' Standard Deviation of 3.16, mean deviation of 2.19, and Risk Adjusted Performance of 0.004 to double-check the risk estimate we provide.
At this time, BioCryst Pharmaceuticals' Common Stock Shares Outstanding is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 542.8 M in 2024, despite the fact that Total Stockholder Equity is likely to grow to (432.8 M). . Price Earnings To Growth Ratio is likely to rise to 0.47 in 2024, whereas Price To Sales Ratio is likely to drop 3.30 in 2024. BioCryst Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 3rd of March 1994 | 200 Day MA 6.5787 | 50 Day MA 7.6552 | Beta 1.887 |
BioCryst |
Sharpe Ratio = -0.0229
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCRX |
Estimated Market Risk
| 3.16 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioCryst Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioCryst Pharmaceuticals by adding BioCryst Pharmaceuticals to a well-diversified portfolio.
Price Book 56.5858 | Enterprise Value Ebitda (12.20) | Price Sales 3.8155 | Shares Float 192.7 M | Wall Street Target Price 14.6364 |
BioCryst Pharmaceuticals Main Headline on 28th of March 2024
Disposition of 7525 shares by Thackray Helen M. of BioCryst ... by Thackray Helen M.
Filed transaction by BioCryst Pharmaceuticals Officer: Chief R&d Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
BioCryst Pharmaceuticals Valuation on March 31, 2024
It is possible to determine the worth of BioCryst Pharmaceuticals on a given historical date. On March 31, 2024 BioCryst was worth 5.2 at the beginning of the trading date compared to the closed value of 5.08. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of BioCryst Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find BioCryst Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioCryst Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against BioCryst Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 5.04 | 5.21 | 4.97 | 5.15 | 2,990,374 | |
03/28/2024 | 5.20 | 5.34 | 5.06 | 5.08 | 3,491,454 |
| 5.04 | 5.09 | 4.91 | 5.05 | 4,874,775 |
| Backtest BioCryst Pharmaceuticals | | | BioCryst Pharmaceuticals History | | | BioCryst Pharmaceuticals Valuation | Previous | Next |
BioCryst Pharmaceuticals Trading Date Momentum on March 31, 2024
| On April 01 2024 BioCryst Pharmaceuticals was traded for 5.05 at the closing time. The top price for the day was 5.09 and the lowest listed price was 4.91 . The trading volume for the day was 4.9 M. The trading history from April 1, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 0.59% . The overall trading delta against the current closing price is 9.06% . |
BioCryst Pharmaceuticals Fundamentals Correlations and Trends
By evaluating BioCryst Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. BioCryst financial account trend analysis is a perfect complement when working with valuation or volatility modules.About BioCryst Pharmaceuticals Stock history
BioCryst Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for BioCryst is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in BioCryst Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing BioCryst Pharmaceuticals stock prices may prove useful in developing a viable investing in BioCryst Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 192.2 M | 201.8 M | |
| Net Loss | -222.4 M | -211.3 M |
BioCryst Pharmaceuticals Quarterly Net Working Capital |
|
BioCryst Pharmaceuticals Stock Technical Analysis
BioCryst Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
BioCryst Pharmaceuticals Period Price Range
Low | November 24, 2024
| High |
0.00 | 0.00 |
BioCryst Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
BioCryst Pharmaceuticals November 24, 2024 Market Strength
Market strength indicators help investors to evaluate how BioCryst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioCryst Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying BioCryst Pharmaceuticals stock market strength indicators, traders can identify BioCryst Pharmaceuticals entry and exit signals to maximize returns
BioCryst Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for BioCryst Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of BioCryst Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of BioCryst to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.004 | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.01) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.